Durvalumab User Reviews & Ratings
Brand names: Imfinzi
Durvalumab has an average rating of 6.0 out of 10 from a total of 2 reviews on Drugs.com. 50% of reviewers reported a positive experience, while 0% reported a negative experience.
Condition | Avg. Rating | Reviews | Compare |
---|---|---|---|
Non Small Cell Lung Cancer | 2 reviews for Non Small Cell Lung Cancer | 57 medications | |
Add your review |
- Anonymous
- Taken for 6 months to 1 year
- April 1, 2024
Imfinzi (durvalumab) for Non Small Cell Lung Cancer "Had 12 treatments after completion of chemoradiation. Medication was well tolerated with minimal side effects."
Reviews may be edited to correct grammar/spelling or to remove inappropriate language and content. Reviews that appear to be created by parties with a vested interest are not published. This information is not intended to endorse any particular medication. While these reviews may be helpful, they are not a substitute for the expertise, knowledge, and judgement of healthcare professionals.
More about durvalumab
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- Breastfeeding
- En español
For Non Small Cell Lung Cancer "During immunotherapy treatment for one year, I developed constipation, horrible itching all over my body with no relief from creams or any other treatments. Also, it shrunk my thyroid gland, so that I will have to stay on thyroid medicine for the rest of my life. I hope it worked on the cancer. We shall see."